- Published on
RonanRX (YC S26) – Personalized Peptides and GLP-1s
- Authors
- Name
- DeepHorus
RonanRX, a new startup from Y Combinator's S26 batch, is launching a service to provide personalized GLP-1 treatments via text message. The platform aims to address the limitations of standard, one-size-fits-all dosing regimens for popular weight-loss medications. Its core premise is that individual patient history and physiology should dictate the treatment plan, not a fixed pharmaceutical label.
The service targets a significant gap in the current GLP-1 market. Many patients experience common side effects like nausea and fatigue, which often lead them to quit treatment. Furthermore, the high cash-pay list prices for brand-name GLP-1s can make sustained care financially unsustainable. RonanRX argues that personalized medicine can improve both tolerability and long-term adherence.
The RonanRX process begins with a simple, free text-based intake. A licensed physician then reviews the patient's history and medical data to create a tailored plan. This includes setting a specific starting dose and titration schedule, moving away from standardized protocols.
A key differentiator is the potential inclusion of patient-specific adjuncts. Depending on an individual's response, a physician may add supportive medications like B12 or anti-nausea agents to manage side effects. The company emphasizes that the plan is built around the patient, not the drug molecule itself.
Every prescription is part of a controlled "authority chain." The physician writes the specific order, and a licensed pharmacist at the patient's selected pharmacy verifies and releases only what was prescribed. RonanRX highlights that compounded, patient-specific preparations can often cost less than cash-pay brand-name list prices, offering a more affordable alternative.
The company positions itself as providing a complete care experience, not just a number on a scale. This includes a consistent dosage from the start and ongoing physician oversight. Looking ahead, RonanRx is already expanding its scope, with a waitlist now open for hormone replacement therapy (HRT) services.
RonanRX enters a competitive telehealth space but focuses squarely on personalization and clinical rigor. Its model relies on the collaboration between a reviewing physician and a dispensing pharmacist. As the platform scales, it will navigate varying state regulations concerning compounded medications and pharmacy access.
